Economic Analysis of Batch and Continuous Biopharmaceutical Antibody Production: a Review
- 92 Downloads
There is a growing interest in continuous biopharmaceutical processing due to the advantages of small footprint, increased productivity, consistent product quality, high process flexibility and robustness, facility cost-effectiveness, and reduced capital and operating cost. To support the decision making of biopharmaceutical manufacturing, comparisons between conventional batch and continuous processing are provided.
Various process unit operations in different operating modes are summarized. Software implementation as well as computational methods used are analyzed pointing to the advantages and disadvantages that have been highlighted in the literature. Economic analysis methods and their applications in different parts of the processes are also discussed with examples from publications in the last decade.
The results of the comparison between batch and continuous process operation alternatives are discussed. Possible improvements in process design and analysis are recommended. The methods used here do not reflect Lilly’s cost structures or economic evaluation methods.
This paper provides a review of the work that has been published in the literature on computational process design and economic analysis methods on continuous biopharmaceutical antibody production and its comparison with a conventional batch process.
KeywordsEconomic analysis Batch and continuous biopharmaceutical manufacturing Antibody production Simulation software
This work was supported by Eli Lilly and company.
- 1.Newswire PR. Monoclonal antibodies (mAbs) market analysis by source (chimeric, murine, humanized, human), by type of production, by indication (cancer, autoimmune, inflammatory, infectious, microbial, viral diseases), by end-use and segment forecasts, 2013–2024. LON-Reportbuyer: Y; 2017.Google Scholar
- 5.America PRaMo. Medicines in development: biologics 2013 report. Pharmaceutical Research and Manufacturers of America. 2013. http://phrma-docs.phrma.org/sites/default/files/pdf/biologics2013.pdf. Accessed 01 June 2018.
- 7.Newswire PR. Monoclonal antibodies (mAbs) market Size worth $138.6 billion by 2024: grand view research, Inc. bc-Grand-View-Research: Y; 2016.Google Scholar
- 9.Zydney AL. Continuous downstream processing for high value biological products: a review. Biotechnol Bioeng. 2016;113(3):465–75.Google Scholar
- 10.Whitford WG. Single-use systems support continuous bioprocessing by perfusion culture. In: Subramanian G, editor. Continuous processing in pharmaceutical manufacturing. 2014, .Google Scholar
- 14.Farid SS, Pollock J, Ho SV. Evaluating the economic and operational feasibility of continuous processes for monoclonal antibodies. Continuous Processing in Pharmaceutical Manufacturing. Wiley-VCH Verlag GmbH & Co. KGaA; 2014;433–56. https://doi.org/10.1002/9783527673681.ch17.
- 22.Petrides D. Bioprocess design and economics. In: Roger G. Harrison PWT, Scott R. Rudge and Demetri P. Petrides, editor. Bioseparations Science and Engineering 2ed., 2015.Google Scholar
- 23.Chatterjee S, editor. FDA perspective on continuous manufacturing. IFPAC Annual Meeting; 2012; Baltimore: FDA U.S. Food and Drug Administration Protecting and Promoting Public Health.Google Scholar
- 25.Novais JL, Titchener-Hooker NJ, Hoare M. Economic comparison between conventional and disposables-based technology for the production of biopharmaceuticals. Biotechnol Bioeng. 2001;75(2):143–53.Google Scholar
- 27.Liu HF, Ma J, Winter C, Bayer R. Recovery and purification process development for monoclonal antibody production. Mabs-Austin. 2010;2(5):480–99.Google Scholar
- 29.Kelley B. Industrialization of mAb production technology: the bioprocessing industry at a crossroads. Mabs-Austin. 2009;1(5):443–52.Google Scholar
- 31.Patil R, Walther J. Continuous manufacturing of recombinant therapeutic proteins: upstream and downstream technologies. Adv Biochem Eng Biotechnol. 2017. https://doi.org/10.1007/10_2016_58.
- 39.Torres-Acosta MA, Mayolo-Deloisa K, González-Valdez J, Rito-Palomares M. Aqueous two-phase systems at large scale: challenges and opportunities. Biotechnol J. 0(0):1800117. https://doi.org/10.1002/biot.201800117.
- 43.Shinkazh O, inventor Countercurrent tangential chromatography methods, systems, and apparatus. US2011.Google Scholar
- 47.Ransohoff TC. Bisschops MAT. Google Patents: Continuous processing methods for biological products; 2013.Google Scholar
- 48.Coffman J, Goby J, Godfrey S, Orozco R, Vogel JH. Methods, apparatuses, and systems for continuously inactivating a virus during manufacture of a biological product. Google Patents; 2017.Google Scholar
- 56.Rathore AS, Kateja N, Kumar D. Process integration and control in continuous bioprocessing. Curr Opin Chem Eng. 2018;22:18–25.Google Scholar
- 57.Flickinger MC. Upstream industrial biotechnology. John Wiley & Sons.Google Scholar
- 58.Castilho LR. Continuous animal cell perfusion processes: the first step toward integrated continuous biomanufacturing. In: Subramanian G, editor. Continuous Processing in Pharmaceutical Manufacturing 2015.Google Scholar
- 59.Lee R, Mikol V, Allen E, Ruetsch N, Cameron B, Oligino T et al. Humanized anti-CXCR5 antibodies, derivatives thereof and their use. Google Patents; 2011.Google Scholar
- 65.Torres-Acosta MA, Aguilar-Yanez JM, Rito-Palomares M, Titchener-Hooker NJ. Economic analysis of uricase production under uncertainty: contrast of chromatographic purification and aqueous two-phase extraction (with and without PEG recycle). Biotechnol Prog. 2016;32(1):126–33. https://doi.org/10.1002/btpr.2200.Google Scholar
- 67.Arnold L, Lee K, Rucker-Pezzini J, Lee JH. Implementation of fully integrated continuous antibody processing: effects on productivity and COGm. Biotechnol J. 2018. https://doi.org/10.1002/biot.201800061.
- 68.Hummel J, Pagkaliwangan M, Gjoka X, Davidovits T, Stock R, Ransohoff T, et al. Modeling the downstream processing of monoclonal antibodies reveals cost advantages for continuous methods for a broad range of manufacturing scales. Biotechnol J. 2018. https://doi.org/10.1002/biot.201700665.
- 69.Grilo AL, Mateus M, Aires-Barros MR, Azevedo AM. Monoclonal antibodies production platforms: an opportunity study of a non-protein-A chromatographic platform based on process economics. Biotechnol J. 2017;12(12). https://doi.org/10.1002/biot.201700260.
- 70.The biopharmaceutical industry’s leading process analysis and economic modelling package. In: BioSolve Process 7. Biopharm. 2016. https://biopharmservices.com/wp-content/uploads/2016/02/Process-2pp-A4-2016-2-FINAL.pdf. Accessed 8/9 2017.
- 71.Aspentech. Aspen Batch Process Developer https://www.aspentech.com/en/products/pages/aspen-batch-process-developer. Accessed 12/19 2018.
- 72.Aspentech. Aspen Chromatogrpahy. https://www.aspentech.com/en/products/pages/aspen-chromatography. Accessed 12/19 2018.
- 73.Ashouri P. A dynamic simulation framework for biopharmaceutical capacity management: University College London; 2011.Google Scholar
- 75.Towler G, Sinnott RK. Chemical engineering design: principles, practice and economics of plant and process design: Elsevier; 2012.Google Scholar
- 76.Hernandez I, Bott SW, Patel AS, Wolf CG, Hospodar AR, Sampathkumar S, et al. Pricing of monoclonal antibody therapies: higher if used for cancer? Am J Manag Care. 2018;24(2):109–+.Google Scholar
- 77.Pannell DJ. Sensitivity analysis: strategies, methods, concepts, examples. Agric Econ. 1997;16:139–52.Google Scholar
- 80.Repligen inspiring advances in bioprocessing. Frequently asked questions—perfusion. Repligen inspiring advances in bioprocessing official web-site. 2017. https://www.repligen.com/products/upstream-solutions/xcell-atf-cell-retention-system/faq-perfusion/#steady. Accessed 1 June 2018.
- 82.Roque ACA, Lowe CR, Taipa MÂ. Antibodies and genetically engineered related molecules: production and purification. Biotechnol Prog. 2004;20(3):639–54.Google Scholar
- 84.Farid SS. Economic drivers and trade-offs in antibody purification processes. BioPharm International. 2009; 2009(7).Google Scholar
- 86.Espitia-Saloma E, Vazquez-Villegas P, Rito-Palomares M, Aguilar O. An integrated practical implementation of continuous aqueous two-phase systems for the recovery of human IgG: from the microdevice to a multistage bench-scale mixer-settler device. Biotechnol J. 2016;11(5):708–16. https://doi.org/10.1002/biot.201400565.Google Scholar
- 91.Torres-Acosta MA, Pereira JFB, Freire MG, Aguilar-Yanez JM, Coutinho JAP, Titchener-Hooker NJ, et al. Economic evaluation of the primary recovery of tetracycline with traditional and novel aqueous two-phase systems. Sep Purif Technol. 2018;203:178–84. https://doi.org/10.1016/j.seppur.2018.04.041.Google Scholar
- 93.Berthold Boedeker JM. Opportunities and limitations of continuous processing and use of disposables. Am Pharm Rev. 2017.Google Scholar
- 96.Marc Bisschops LF, Scott Fulton, Tom Ransohoff. Single-use, continuous-countercurrent, multicolumn chromatography. BioProcess International. 2009.Google Scholar
- 97.Michael LaBreck MP. An economic analysis of single—use tangential flow filtration for biopharmaceutical applications. BioProcess International. 2010;2010 Supplement(8).Google Scholar
- 100.Magnus J, Temming M, Schwan P, Micovic J, Lobedam M, Sievers S, editors. A biomanufacturing facility based on continuous processing and single use technology2015.Google Scholar
- 102.Farid SS. Established bioprocesses for producing antibodies as a basis for future planning. In: Hu W-S, editor. Cell Culture Engineering. Berlin, Heidelberg: Springer Berlin Heidelberg; 2006. p. 1–42.Google Scholar
- 109.Shirokov VA, Simonenko PN, Biryukov SV, Spirin AS. Continuous-flow and continuous-exchange cell-free translation systems and reactors. In: Spirin AS, editor. Cell-free translation systems. Berlin, Heidelberg: Springer Berlin Heidelberg; 2002. p. 91–107.Google Scholar
- 111.Dutta AK, Tran T, Napadensky B, Teella A, Brookhart G, Ropp PA, et al. Purification of monoclonal antibodies from clarified cell culture fluid using Protein A capture continuous countercurrent tangential chromatography. J Biotechnol. 2015;213:54–64. https://doi.org/10.1016/j.jbiotec.2015.02.026.Google Scholar
- 116.Fisher AC, Kamga MH, Agarabi C, Brorson K, Lee SL, Yoon S. The current scientific and regulatory landscape in advancing integrated continuous biopharmaceutical manufacturing. Trends Biotechnol. 2018. https://doi.org/10.1016/j.tibtech.2018.08.008.